From following PD-1 to leading multiple ADCs, Lupe Pharmaceuticals-B (02157) welcomes a reevaluation of its value?

As a newcomer in the field of tumor treatment, Luopu Biosciences-B (02157.HK) is well known in the capital market for its PD-1. However, since its initial public offering, Luopu Biosciences' stock performance has not been satisfactory, as it was initially only known for its fast progress in PD-1. According to Wind data, Luopu Biosciences' current stock price is still only half of its initial public offering in 2022. It is worth noting that this year, Luopu Biosciences' stock price has once again attracted the attention of the capital market, with a cumulative increase of nearly 78% from the beginning of the year, leading in the biotechnology sector in Hong Kong.